Skip to content
Home
Meetings Archive
Browse By Category
Browse By Keyword
Search
Home
Meetings Archive
Browse By Category
Browse By Keyword
Search
Search
2020-05-20T12:01:36-05:00
Search
Search by Abstract Number, Title, Keyword, or Authors
Search by...
All
Authors and Affiliations
Title
Abstract Number
Keyword
Category
All
Clinical Vignettes
Innovations
Research
Sub-Category
(Optional)
Select Sub-Category...
Adult
Communication
Consultative Medicine
Education
Finalist
Geriatrics
Other
Outcomes Research
Patient Safety
Pediatric
Pediatrics
Perioperative
Quality Improvement
Technology in Hospital Medicine
Transitions of Care
Translating Research into Practice
Uncategorized
Value in Hospital Medicine
Winners
Session Type
Select Session Type...
Oral Presentations
Plenary Presentations
Meeting
All Meetings
SHM Converge 2024
SHM Converge 2023
SHM Converge 2022
SHM Converge 2021
Hospital Medicine 2020, Virtual Competition
Hospital Medicine 2019, March 24-27, National Harbor, Md.
Hospital Medicine 2018; April 8-11; Orlando, Fla.
Hospital Medicine 2017, May 1-4, 2017; Las Vegas, Nev.
Hospital Medicine 2016, March 6-9, San Diego, Calif.
Hospital Medicine 2015, March 29-April 1, National Harbor, Md.
Hospital Medicine 2014, March 24-27, Las Vegas, Nev.
Hospital Medicine 2013, May 16-19, National Harbor, Md.
Hospital Medicine 2012, April 1-4, San Diego, Calif.
Hospital Medicine 2011, May 10-13, Dallas, Texas.
Hospital Medicine 2010, April 8-11, Washington, D.C.
Hospital Medicine 2009, May 14-17, Chicago, Ill.
Hospital Medicine 2008, April 3-5, San Diego, Calif.
Hospital Medicine 2007, May 23-25, Dallas, Texas
Hospital Medicine 2006, May 3-5, Washington, D.C.
Search Results for
biotherapeutic
Abstract Number: A7
SAFETY OF INVESTIGATIONAL MICROBIOTA-BASED LIVE BIOTHERAPEUTIC RBX2660 IN INDIVIDUALS WITH RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION: DATA FROM 5 PROSPECTIVE CLINICAL STUDIES
SHM Converge 2022
Background: Microbiota-based treatments have shown promise to reduce recurrence for recurrent Clostridioides difficile infections (rCDI), but consistent and reliable safety data are needed to support regulatory approvals and broaden patient access. Here we provide cumulative safety data from 5 prospective clinical studies evaluating RBX2660—a standardized, microbiota-based investigational live biotherapeutic—for reducing rCDI. Methods: This analysis included […]
Abstract Number: E6
MICROBIOTA-BASED BIOTHERAPEUTIC RBX2660 IMPROVES CLOSTRIDIOIDES DIFFICILE INFECTION OUTCOMES IN A REAL-WORLD POPULATION: A RETROSPECTIVE STUDY OF USE UNDER ENFORCEMENT DISCRETION
SHM Converge 2022
Background: Recurrent Clostridioides difficile infection (rCDI) is an urgent public health threat. RBX2660 is a standardized, stabilized, investigational microbiota-based live biotherapeutic that has been evaluated in 5 prospective clinical trials. Eligibility criteria in clinical trials are often narrowly defined, excluding broader patient populations. Herein, we report a retrospective analysis of safety and efficacy of RBX2660 […]
Page load link
Go to Top